Axiomer RNA editing shows strong phase 1 proof-of-concept for biliary atresia; key 2026–27 catalysts ahead. Click to read ...

RAP-219 Phase 3 catalyst, cash runway to 2029, long half-life pros/cons, valuation. Click here to read my analysis.

A research team led by Yang Lu from the Department of Mechanical Engineering at the Faculty of Engineering, The University of ...

Argenx stock is trading near $1,050 on the Nasdaq as of late August 2026, with recent trial success for VYVGART Hytrulo and ...

When different materials transition from one phase to another, such as water coming to a boil or a magnet losing its ability ...

August 21, 2026 - PRESSADVANTAGE - GULLCO International, a manufacturer of welding and cutting automation equipment, ...

The European Medicines Agency (EMA) is holding a consultation about a draft framework intended to cut the time it takes to ...

Metabones is bringing its TruePDAF Technology to Fujifilm cameras, and they have new products that completely replace the ...

An oncology drug abandoned decades ago is getting a second look, with new research uncovering a mechanism that could offer an ...

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, today announced the closing of a $66 ...

The research by members of the HKU Nanomechanics Laboratory, Professor Yang Lu (left), PhD student Mr Jiayi Li (center), and ...

Results point to the hypothalamic-pituitary-adrenal axis as a promising therapeutic target ...